Neuren Pharmaceuticals Achieves Major Sales Milestone with DAYBUE™

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.

Neuren Pharmaceuticals has received a US$50 million sales milestone payment following the successful commercialization of DAYBUE™ (trofinetide) in North America, where 2024 net sales reached US$348.4 million. This milestone reflects the growing market presence of DAYBUE and highlights Neuren’s strategic partnership with Acadia Pharmaceuticals, positioning the company strongly within the neurological disorder treatment industry.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals is a company focused on developing drug therapies for serious neurological disorders that emerge in early childhood, with limited or no approved treatment options. The company has received ‘orphan drug’ designation in the United States for its programs, which provides incentives for developing therapies for rare and serious diseases. Neuren’s product, DAYBUE™ (trofinetide), is approved for the treatment of Rett syndrome and is licensed to Acadia Pharmaceuticals for development and commercialization. Neuren is also developing NNZ-2591 for multiple neurodevelopmental disorders.

YTD Price Performance: 10.82%

Average Trading Volume: 588

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $1.07B

See more data about NEU stock on TipRanks’ Stock Analysis page.